Clinical Study | Office of Clinical Research

Phase II/III Biomarker-Driven Master Protocol For Second Line Therapy Of Squamous Cell Lung Cancer (Screening Step).

Posted Date: May 15, 2019

Investigator: John Morris
Type of Study: Drug

The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it i

Criteria:

To Be Eligible For This Study, Patients Must Have Squamous Cell Lung Cancer.

Keywords:

Cancer, Lung Cancer, S1400, Squamous Cell

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List